Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celltrion Inc.

www.celltrion.com/en

Latest From Celltrion Inc.

Glenmark On Course For Xolair Biosimilar Deal, US Capital Raise For Innovation

Glenmark appears close to sewing up a deal for its biosimilar version of Novartis/Genentech's Xolair amid the firm's ongoing focus on partnering out some key assets. It also expects to kick off plans to raise capital in the US for its innovation business in Q4 of fiscal 2019-20.

Commercial Strategy

Pooled Data Among AAM’s Concerns On FDA’s Therapeutic Protein Biosimilars Guidance

Three key areas for improvement in in the FDA’s draft guidance on therapeutic protein biosimilars have been highlighted by industry association AAM. Pharmaceutical giants such as Pfizer, Novartis and Celltrion have also expressed concerns highlight shortcomings and sought clarification.

Biosimilars Regulation

Mylan-Biocon’s Ogivri First Off Block In Australia But Competition In Sight

Mylan-Biocon’s biosimilar Herceptin debuts in Australia, promising to provide patients a high quality and affordable alternative, though at least three competing trastuzumab versions including Amgen’s Kanjinti are in the wings.

Australia Biosimilars

Mylan-Biocon’s Ogivri First Off Block In Australia But Competition In Sight

Mylan-Biocon’s biosimilar Herceptin debuts in Australia, promising to provide patients a high quality and affordable alternative, though at least three competing trastuzumab versions including Amgen’s Kanjinti are in the wings.

Australia Biosimilars
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Generic Drugs
  • Services
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Gastrointestinal
  • Immune Disorders
  • Infectious & Viral Diseases
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Celltrion Inc.
  • Senior Management
  • Hyoung-Ki Kim, Co-CEO
  • Contact Info
  • Celltrion Inc.
    Phone: (82) 32 850 5000
    23 Academy-ro
    Yeonsu-gu
    Incheon City, 406-840
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register